Chester County News and Community Website
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), headquartered in Exton, PA, is a clinical-stage biotechnology company focused on taking the next step in immuno-oncology therapies.
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced the closing of a second tranche under its April 7, 2020, securities purchase agreement, resulting in aggregate proceeds of up to …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO). Mr. Soland …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) reported its financial and operational results for the third quarter ended September 30, 2020.
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that final data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented in …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) reported its financial and operational results for the second quarter ended June 30, 2020.
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced entering into an agreement with a fund affiliated with institutional investors providing for a private placement exempt from the registration requirements …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) had provided notice of a change in the location for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) via the filing …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented …
Read More